Intracerebroventricular Cerliponase Alfa for CLN2 Disease: Clinical Practice Considerations from US Clinics

被引：0
|
作者：
de los Reyes, E.
Lehwald, L.
Wang, R.
Augustine, E.
Berry-Kravis, E.
Butler, K.
Cormier, N.
Demarest, S.
Lu, S.
Madden, J.
Olaya, J.
See, S.
Vierhile, A.
Yang, A.
Leal-Pardinas, F.
机构：
来源：
ANNALS OF NEUROLOGY | 2019年 / 86卷
关键词：
Rare Diseases;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
205
引用
收藏
页码：S136 / S136
页数：1
相关论文
共 50 条
  • [31] Cerliponase alfa for the treatment of CLN2 disease in a patient cohort including children younger than three years: Interim results from an ongoing clinical study
    Schulz, Angela
    de los Reyes, Emily
    Specchio, Nicola
    Gissen, Paul
    Slasor, Peter
    Bondade, Shailesh
    Jacoby, David
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S95 - S95
  • [32] Cerliponase alfa for treatment of CLN2 disease in a patient cohort including children <3 years old: Interim results from an ongoing clinical study
    Schulz, Angela
    de los Reyes, Emily
    Specchio, Nicola
    Gissen, Paul
    Slasor, Peter
    Bondade, Shailesh
    Cohen-Pfeffer, Jessica
    Jacoby, David
    EPILEPSIA, 2021, 62 : 32 - 33
  • [33] Persistent Treatment Effect Of Cerliponase Alfa In Children With CLN2 Disease: A 3 Year Update From An Ongoing Multicenter Extension Study
    Specchio, N.
    Schulz, A.
    Gissen, P.
    de los Reyes, E.
    Cahan, H.
    Slasor, P.
    Jacoby, D.
    Ajayi, T.
    EPILEPSIA, 2019, 60 : 157 - 157
  • [34] Real-world clinical outcomes of intraventricular cerliponase alfa in CLN2 disease: 4.5-year update from an independent ongoing observational study
    Schulz, Angela
    Schwering, Christoph
    Wibbeler, Eva
    Westermann, Lena
    Dulz, Simon
    Lezius, Susanne
    Nickel, Miriam
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S109 - S109
  • [35] Persistent treatment effect of cerliponase alfa in children with CLN2 disease: A > 4 year update from an ongoing multicenter extension study
    Schulz, Angela
    Specchio, Nicola
    Gissen, Paul
    de los Reyes, Emily
    Slasor, Peter
    Jacoby, David
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S145 - S145
  • [36] Intravitreal Cerliponase alfa slows the rate of retinal thinning in patients with CLN2 type Batten Disease: A first in man report
    Henderson, Robert
    Wawrzynski, James
    Martinez, Ana Rodriguez
    Bowman, Richard
    Whiteley, Rebecca
    Gan, Chin
    Harding, Louise
    Mortensen, Amanda
    Thompson, Dorothy
    Gissen, Paul
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [37] Cerliponase alfa for the treatment of CLN2 disease in an expanded patient cohort including children younger than three years: Interim results from an ongoing clinical study
    Schulz, Angela
    de los Reyes, Emily
    Specchio, Nicola
    Gissen, Paul
    Cahan, Heather
    Slasor, Peter
    Ajayi, Temitayo
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S145 - S145
  • [38] Cerliponase Alfa for the Treatment of CLN2 Disease in an Expanded Patient Cohort Including Children Younger than Three Years: Interim Results from an Ongoing Clinical Study
    Schulz, A.
    de los Reyes, E.
    Specchio, N.
    Gissen, P.
    Cahan, H.
    Slasor, P.
    Ajayi, T.
    ANNALS OF NEUROLOGY, 2019, 86 : S144 - S144
  • [39] Serial brain MRI volumetrics and tractography of atypical CLN2 patients receiving ICV cerliponase alfa treatment
    Kao, Audrey
    Chang, Harriet
    Nestrasil, Igor
    Wang, Raymond Y.
    MOLECULAR GENETICS AND METABOLISM, 2025, 144 (02) : 60 - 61
  • [40] Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2)
    Gutic, Medo
    Milosavljevic, Milos N.
    Safiye, Teodora
    Milidrag, Ardea
    Jankovic, Slobodan M.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (05) : 561 - 570
12345